Effects of carvedilol on structural and functional outcomes and plasma biomarkers in the mouse transverse aortic constriction heart failure model:

摘要

Introduction:Despite the widespread use of the mouse transverse aortic constriction heart failure model, there are no reports on the characterization of the standard-of-care agent carvedilol in this model.Methods:Left ventricular pressure overload was produced in mice by transverse aortic constriction between the innominate and left common carotid arteries. Carvedilol was administered at multiple dose levels (3, 10 and 30?mg/kg/day per os; yielding end-study mean plasma concentrations of 0.002, 0.015 and 0.044?μM, respectively) in a therapeutic design protocol with treatment initiated after the manifestation of left ventricular remodeling at 3?weeks post transverse aortic constriction and continued for 10?weeks.Results:Carvedilol treatment in transverse aortic constriction mice significantly decreased heart rate and left ventricular dP/dt (max) at all dose levels consistent with β-adrenoceptor blockade. The middle dose of carvedilol significantly decreased left ventricular weight, whereas the higher dose ...